In July 2019, the creation of a new company combining Mylan with Upjohn was announced. Together, their strengths offered a unique and powerful platform to change healthcare in ways that hadn’t been realised before.

Mylan brought a diverse portfolio across many geographies and key therapeutic areas as well as a robust pipeline, high quality manufacturing and supply chain excellence. Upjohn brought trusted, iconic brands and proven commercialisation capabilities, including leadership positions in China and other emerging markets. Upjohn’s focus on noncommunicable diseases paired nicely with Mylan’s long history of fighting infectious disease. Combining the two complementary businesses would transform and accelerate the ability of each to serve patients’ needs and expand the companies’ capabilities across more than 165 markets.

Named Viatris, the Mylan-Upjohn combination starts life committed to empowering people to live healthier at every stage of life with some 37,000 employees worldwide, and a sustainable, diverse and differentiated product line and pipeline. Perhaps most important, Viatris has a powerful combination of best-in-class capabilities and world-class management from its founding companies, charting the c+J43:J44ompany’s course for the next decade and beyond: Robert J. Coury as executive chairman, Michael Goettler as chief executive officer, Rajik Malik as president and Sanjeev Narula as chief financial officer.